Co-Authors
This is a "connection" page, showing publications co-authored by Simon Tiberi and Emanuele Pontali.
Connection Strength
1.826
-
The cursed duet today: Tuberculosis and HIV-coinfection. Presse Med. 2017 Mar; 46(2 Pt 2):e23-e39.
Score: 0.706
-
Challenging MDR-TB clinical problems - The case for a new Global TB Consilium supporting the compassionate use of new anti-TB drugs. Int J Infect Dis. 2019 Mar; 80S:S68-S72.
Score: 0.201
-
Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review. Eur Respir J. 2018 07; 52(1).
Score: 0.194
-
Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. Eur Respir J. 2017 11; 50(5).
Score: 0.186
-
Post-implementation blues: the unfulfilled potential of Xpert. Int J Tuberc Lung Dis. 2017 10 01; 21(10):1073.
Score: 0.184
-
Tuberculosis, COVID-19 and hospital admission: Consensus on pros and cons based on a review of the evidence. Pulmonology. 2021 May-Jun; 27(3):248-256.
Score: 0.058
-
Epidemic and pandemic viral infections: impact on tuberculosis and the lung: A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN), and members of the European Society of Clinical Microbiology and Infectious Diseases Study Group for Mycobacterial Infections (ESGMYC). Eur Respir J. 2020 10; 56(4).
Score: 0.057
-
Tuberculosis in the time of COVID-19: quality of life and digital innovation. Eur Respir J. 2020 08; 56(2).
Score: 0.056
-
Burden and Characteristics of the Comorbidity Tuberculosis-Diabetes in Europe: TBnet Prevalence Survey and Case-Control Study. Open Forum Infect Dis. 2019 Jan; 6(1):ofy337.
Score: 0.050
-
Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis. Emerg Infect Dis. 2017 10; 23(10).
Score: 0.046
-
Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J. 2017 05; 49(5).
Score: 0.045
-
Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review. Int J Mol Sci. 2017 Feb 07; 18(2).
Score: 0.044